New Insights into the Latest Advancement in a-Amylase Inhibitors of Plant Origin with Anti-Diabetic Effects

被引:49
作者
Kashtoh, Hamdy [1 ]
Baek, Kwang-Hyun [1 ]
机构
[1] Yeungnam Univ, Dept Biotechnol, Gyongsan 38541, South Korea
来源
PLANTS-BASEL | 2023年 / 12卷 / 16期
基金
新加坡国家研究基金会;
关键词
alpha-amylase; anti-diabetic activity; postprandial hyperglycemia; extract; natural compounds; type; 2; diabetes; PANCREATIC ALPHA-AMYLASE; DIABETES-MELLITUS; IN-VITRO; GLUCOSIDASE INHIBITORS; ANGSTROM RESOLUTION; STARCH DIGESTION; HUMAN SALIVARY; POLYSACCHARIDES; CARBOHYDRATE; IDENTIFICATION;
D O I
10.3390/plants12162944
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The rising predominance of type 2 diabetes, combined with the poor medical effects seen with commercially available anti-diabetic medications, has motivated the development of innovative treatment approaches for regulating postprandial glucose levels. Natural carbohydrate digestion enzyme inhibitors might be a viable option for blocking dietary carbohydrate absorption with fewer side effects than manufactured medicines. Alpha-amylase is a metalloenzyme that facilitates digestion by breaking down polysaccharides into smaller molecules such as maltose and maltotriose. It also contributes to elevated blood glucose levels and postprandial hyperglycemia. As a result, scientists are being urged to target a-amylase and create inhibitors that can slow down the release of glucose from carbohydrate chains and prolong its absorption, thereby resulting in lower postprandial plasma glucose levels. Natural a-amylase inhibitors derived from plants have gained popularity as safe and cost-effective alternatives. The bioactive components responsible for the inhibitory actions of various plant extracts have been identified through phytochemical research, paving the way for further development and application. The majority of the findings, however, are based on in vitro investigations. Only a few animal experiments and very few human investigations have confirmed these findings. Despite some promising results, additional investigation is needed to develop feasible anti-diabetic drugs based on plant-derived pancreatic a-amylase inhibitors. This review summarizes the most recent findings from research on plant-derived pancreatic a-amylase inhibitors, including plant extracts and plant-derived bioactive compounds. Furthermore, it offers insights into the structural aspects of the crucial therapeutic target, a-amylases, in addition to their interactions with inhibitors.
引用
收藏
页数:28
相关论文
共 24 条
  • [21] The Immune-Stimulating and Anti-Diabetic Effects of Allium hookeri Leaves Grown in a Plant Factory with Artificial Lights in Immunosuppressed Obese C57BL/6 Mice
    Jung, Jieun
    Kim, Ji-Su
    Jeong, Un-Yul
    Bae, Ui-Jin
    Kim, Mina
    Park, Shin-Young
    Hwang, In-Guk
    Heo, Jeong-Wook
    Shim, Chang-Ki
    Ham, Jun-Sang
    Lee, Sung-Hyen
    PHARMACEUTICALS, 2024, 17 (01)
  • [22] New cycloalkyl[b]thiophenylnicotinamide-based α-glucosidase inhibitors as promising anti-diabetic agents: Synthesis, in silico study, in vitro and in vivo evaluations
    Wang, Kai-Ming
    Ge, Yong-Xi
    Zhang, Jie
    Chen, Yi-Tong
    Zhang, Nai-Yu
    Gu, Jin-Song
    Fang, Lei
    Zhang, Xin-Lei
    Zhang, Juan
    Jiang, Cheng-Shi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
  • [23] Ultrasound mediated nano ZnO catalyzed synthesis of new α-aminophosphonates as potential anti-diabetic agents; an in silico ADMET, molecular docking study, α-amylase and α-glucosidase inhibitory activity
    Subramanyam, CH.
    Kumar, K. Kiran
    Ramana, K. Venkata
    Malar, C. Gladis Raja
    Mohan, S.
    Nagalakshmi, V
    SYNTHETIC COMMUNICATIONS, 2023, 53 (23) : 2041 - 2060
  • [24] Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
    Riemma, Maria Antonietta
    Mele, Elena
    Donniacuo, Maria
    Telesca, Marialucia
    Bellocchio, Gabriella
    Castaldo, Giuseppe
    Rossi, Francesco
    De Angelis, Antonella
    Cappetta, Donato
    Urbanek, Konrad
    Berrino, Liberato
    FRONTIERS IN PHARMACOLOGY, 2024, 15